Huaan Securities Co.Ltd(600909) Shouyu Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) buy rating: original “collateral disease syndrome treatment” system, innovative traditional Chinese medicine has broad prospects

Huaan Securities Co.Ltd(600909) 03 issued a research report on March 6, which said that Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) ( Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) .sz, latest price: 26.29 yuan) purchase rating was given for the first time. The reasons for rating mainly include: 1) the policy of traditional Chinese medicine is constantly favorable and the market scale is huge; 2) The three business segments build a core product group, with performance growth and new drug endurance coexisting; 3) The theoretical system of “syndrome treatment of collateral diseases” creates the core competitive barrier of scientific research. Risk tips: industry policy risks; Product R & D risk; Uncertainty of drug sales, etc.